GlassScriptPhysician profile
Howard C Hines
NPI 1285685412
$2,305.06
in general payments reported to CMS, 2019-2025
20 companies · $228 in 2025
The $228 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $133 · 2021: $220 · 2022: $174 · 2023: $335 · 2024: $768 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301 · Education: $30.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.03 |
| Education | $30.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $489.67 | 2021-2024 | Olumiant, Taltz |
| Abbvie INC. | $357.36 | 2020-2024 | |
| Pfizer INC. | $234.41 | 2019-2025 | |
| Merz North America, INC. | $201.60 | 2019 | |
| Janssen Biotech, INC. | $191.63 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $164.43 | 2021-2025 | |
| Galderma Laboratories, L.P. | $122.70 | 2019-2025 | Nemluvio, Oracea, Aklief |
| E.R. Squibb & Sons, L.L.C. | $116.49 | 2021-2024 | Sotyktu |
| Leo Pharma INC. | $82.89 | 2023-2025 | Adbry |
| Incyte Corporation | $76.10 | 2024 | Opzelura |
| Prugen, INC. Pharmaceuticals | $71.97 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $62.23 | 2024 | Zoryve |
| Genentech USA, INC. | $22.63 | 2019 | |
| Revance Therapeutics, INC. | $22.39 | 2024 | Daxxify |
| Celgene Corporation | $17.71 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $17.56 | 2025 | Gomekli |
| Sun Pharmaceutical Industries INC. | $14.70 | 2023 | Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $13.54 | 2025 | Dupixent |
| Dermavant Sciences, INC. | $13.11 | 2022 | |
| Merck Sharp & Dohme LLC | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Hines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.